We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CSF Biomarker Flags Parkinson's Pathology Much Earlier

By LabMedica International staff writers
Posted on 16 Mar 2021
Print article
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Isolated rapid-eye-movement (REM) sleep behavior disorder (IRBD) can be part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia with Lewy bodies years before clinical symptoms appear.

Real-time quaking-induced conversion (RT-QuIC) analysis of cerebrospinal fluid (CSF) has high sensitivity and specificity for the detection of misfolded α-synuclein in patients with Parkinson's disease and dementia with Lewy bodies.

An international team of Neuroscientists working with the University of Edinburgh (Edinburgh, UK) obtained CSF samples by lumbar puncture from patients with video polysomnography-confirmed IRBD recruited at a specialized sleep disorders center in Barcelona, Spain, and from controls free of neurological disease. There were 52 patients with IRBD and 40 healthy controls matched for age, sex and duration of follow-up underwent lumbar puncture between March 23, 2008, and July 16, 2017. CSF samples were stored until analyzed using RT-QuIC.

The team reported that during follow-up, 32 patients (62%) were diagnosed with Parkinson's disease or dementia with Lewy bodies a mean 3.4 years after lumbar puncture, of whom 31 (97%) were α-synuclein positive at baseline. Specifically, 16 people developed Parkinson's (15 of whom were positive for CSF α -synuclein), and 16 developed dementia with Lewy bodies (all were positive for CSF α-synuclein). CSF α-synuclein RT-¬QuIC was positive in 47 (90%) of 52 patients and in four (10%) of 40 healthy controls, resulting in a sensitivity of 90.4% (95% CI 79.4–95.8) and a specificity of 90.0% (95% CI 76.9–96.0).

The average interval for people who were alpha-synuclein positive at baseline to convert to clinically defined Parkinson's or dementia with Lewy bodies was 3.2 years. Patients with IRBD who were α-synuclein negative had lower risk for developing Parkinson's disease or dementia with Lewy bodies at 2, 4, 6, 8, and 10 years of follow-up than patients with IRBD who were α-synuclein positive. During follow-up, none of the controls developed an α-synucleinopathy.

Alison Green, PhD, a Reader in Biochemistry and a senior author of the study, said, “The detection of pathological α-synuclein preceded the development of clinical symptoms by a mean of 3.2 years, with a range of 6 months to 9 years. This is the first step towards having a reliable biomarker for early, pre-symptomatic disease which will enable therapeutic interventions, including potential neuroprotective treatments, to start in a timelier manner.”

The authors concluded that in patients with IRBD, RT-QuIC detects misfolded α-synuclein in the CSF with both sensitivity and specificity of 90%, and α-synuclein positivity was associated with increased risk of subsequent diagnosis of Parkinson's disease or dementia with Lewy bodies. Detection of α-synuclein in the CSF represents a potential prodromal marker of Parkinson's disease and dementia with Lewy bodies. The study was published on March 1, 2021 in the journal Lancet Neurology.


Related Links:
University of Edinburgh

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.